Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate if AZD2066 can relieve the pain arising from painful diabetic neuropathy compared to placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Analgesics

Criteria

Inclusion Criteria:

• Provision of informed consent prior to any study specific procedures.

• Clinical diagnosis of painful diabetic neuropathy.

• non-fertile females

Exclusion Criteria:

• Other pain that may confound assessment of neuropathic pain.

• Ongoing significant peripheral arterial diseases, skin ulcers, or amputation in the lower extremities.

• History of psychotic disorders among first degree relatives.